Who Should Not Take Ozempic: Safety & Medical Contraindications

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is not appropriate for everyone, despite its growing popularity for weight management and glucose control. Individuals with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe pancreatitis, or certain diabetic complications should avoid semaglutide entirely.

Determining suitability for semaglutide requires more than checking a checklist—it demands a comprehensive evaluation of your medical history, genetic risk factors, and current health status. PlexusDx supports precision-focused decisions by integrating clinical assessment with biomarker and genetic insights that reveal individual predispositions in peptide-response pathways.

Absolute Contraindications: When Semaglutide Must Be Avoided

Absolute contraindications are medical conditions that make semaglutide use unsafe. The FDA black-box warning specifically warns against use in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, because semaglutide may increase calcitonin levels and tumor risk.

Severe acute pancreatitis is another absolute contraindication. Patients with a history of pancreatitis may face increased risk of recurrence when using semaglutide. Consultation with a gastroenterologist or endocrinologist is critical before considering treatment if pancreatitis is part of your medical history.

Relative Contraindications and Medical Conditions Requiring Caution

Relative contraindications do not absolutely prevent semaglutide use but require careful evaluation and provider oversight. These include type 1 diabetes, end-stage renal disease, severe gastroparesis, uncontrolled hypertension, and a history of diabetic retinopathy complications. Some patients in these categories may still benefit with close monitoring; others should avoid the medication.

Medical Condition	Risk or Consideration
Type 1 Diabetes	May increase hypoglycemia risk if combined with insulin; typically not first-line therapy
Advanced Kidney Disease (eGFR <15)	Limited safety data; dosing adjustments and monitoring essential
History of Diabetic Retinopathy	Rapid blood sugar changes may worsen retinopathy; ophthalmology clearance advised
Severe Dehydration Risk or GI Disorders	Nausea and vomiting can worsen volume depletion and electrolyte imbalance
Personal or Family History of Thyroid Cancer	FDA black-box warning; contraindicated unless MEN-2 and medullary thyroid cancer ruled out

Medication Interactions and Polypharmacy Concerns

Semaglutide delays gastric emptying, which can affect the absorption and efficacy of other oral medications. Patients taking oral contraceptives, certain antibiotics, or medications requiring specific timing may need dose adjustments or altered administration schedules to maintain therapeutic levels.

Semaglutide also increases insulin sensitivity, requiring adjustment of insulin doses or sulfonylurea therapy in diabetic patients. Starting semaglutide without coordinating with your diabetes regimen can cause dangerously low blood sugar. Your provider must review all current medications and adjust dosing accordingly.

Genetic and Biomarker Considerations in Semaglutide Eligibility

Genetic variants in GLP-1 receptor pathways, FTO gene expression, and melanocortin-4 receptor signaling influence how individuals respond to and tolerate semaglutide. Some genetic profiles are associated with greater weight loss response, while others correlate with increased gastrointestinal side effects or slower drug metabolism.

Understanding your genetic predispositions in peptide-response pathways—including variants like GLP1R rs6923761 and GIPR rs1800437—can inform whether semaglutide is your best option, or whether alternative therapies may be safer and more effective. This genetic context should always inform discussions with your healthcare provider about treatment suitability.

Who Should Have a Detailed Provider Discussion Before Starting Semaglutide

Certain patient populations benefit from extended evaluation before beginning semaglutide, including pregnant or breastfeeding women, patients with active suicidal ideation or severe depression, and those planning surgery within the next three months. Semaglutide's effects on fertility, mental health, and surgical outcomes require individualized assessment.

Patients over age 65, those with multiple comorbidities, and individuals with limited access to regular monitoring should also have thorough provider consultations. PlexusDx works with qualified healthcare providers to ensure comprehensive medical review and genetic insight integration before treatment initiation, supporting safer, more personalized decisions.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual predispositions in key GLP-1 and peptide-response pathways. Variants in GLP1R, GIPR, FTO, and MC4R genes can influence both semaglutide efficacy and tolerability. This genetic information should be interpreted with a qualified healthcare provider to inform whether semaglutide is appropriate for your unique biology.

The genetic test does not predict exact medication response or guarantee outcomes—genetics is one piece of a much larger clinical picture. However, knowing your genetic predispositions can support a more informed conversation with your provider about whether compounded semaglutide, alternative compounded GLP-1 formulations, or other treatments may align better with your risk profile and expected response.

If you have contraindications to semaglutide or uncertain eligibility, discussing your genetic insights alongside your complete medical history with a PlexusDx-partnered provider can clarify which treatment options are safe and most likely to be effective. This precision approach reduces trial-and-error treatment and supports more confident clinical decisions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at from $209/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.